Evidence map›Paper›PMID 34014592›Full record

Observational studyCancer science2021

Long-term outcomes of androgen deprivation therapy in prostate cancer among Japanese men over 80 years old.

Leandro Blas, Mizuki Onozawa, Masaki Shiota, Shiro Hinotsu, Shinichi Sakamoto, Yasuhide Kitagawa, Taketo Kawai, Masatoshi Eto, Haruki Kume, Hideyuki Akaza and 1 more

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Leandro BlasDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Mizuki OnozawaDepartment of Urology, Narita Hospital, International University of Health and Welfare, Chiba, Japan.
Masaki ShiotaDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.ORCID https://orcid.org/0000-0002-3306-4858
Shiro HinotsuDepartment of Biostatistics and Clinical Epidemiology, Sapporo Medical University, Sapporo, Japan.
Shinichi SakamotoDepartment of Urology, Graduate School of Medicine, Chiba University, Chiba, Japan.ORCID https://orcid.org/0000-0002-7508-7521
Yasuhide KitagawaDepartment of Urology, Komatsu Municipal Hospital, Komatsu, Japan.
Taketo KawaiDepartment of Urology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Masatoshi EtoDepartment of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Haruki KumeDepartment of Urology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9841-0857
Hideyuki AkazaResearch Center for Advanced Science and Technology, University of Tokyo, Tokyo, Japan.
Japan Study Group of Prostate Cancer (J-CaP)
Kyushu University · JPThe University of Tokyo · JPChiba University · JPInternational University of Health and Welfare · JPKomatsu (Japan) · JPSapporo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to analyze the survival rate and to examine the risk of death from prostate cancer when accounting for competing risk of death, in men aged ≥80 y treated with primary androgen deprivation therapy (ADT). Data of patients with prostate cancer who had received ADT were extracted from a nationwide community-based database established by the Japan Study Group for Prostate Cancer. Prognostic variables, including progression-free survival, cancer-specific survival, overall survival, and death rates were compared between men stratified by prostate cancer risk. Overall, 4760 patients older than 80 y were included. The proportion of low-, intermediate-, high-, or very high-risk, regional, and metastatic prostate cancer among super-elderly men was 9.5%, 14.6%, 48.8%, 9.0%, 3.2%, and 24.9%, respectively. Survival rates decreased with increasing risk stratification. The cumulative 5-y death rate by prostate cancer for low-, intermediate-, high-, or very high-risk, regional, and metastatic prostate cancer, was 0.92% (95% confidence interval [CI]: 0.2%-3.6%), 1.6% (95% CI: 0.8%-3.4%), 5.75% (95% CI: 4.25%-7.75%), 15.6% (95% CI: 11.6%-23.3%), 20.7% (95% CI: 13.1%-31.7%), and 36.9% (95% CI: 32.8%-41.4%), respectively. Our findings support that there is no need for immediate ADT for low- and intermediate-risk groups. Conversely, in high- or very high-risk, regional, and metastatic prostate cancer, more efforts for curative therapy and intensive therapy are needed in selected patients.

Indexed as

AgedAged, 80 and overAndrogen AntagonistsDatabases, FactualHumansJapanMaleNeoplasm MetastasisPrognosisProstatic NeoplasmsRetrospective StudiesRisk AssessmentSurvival RateTreatment OutcomeAndrogen Antagonistsandrogen deprivation therapyelderlyJapan Study Group for Prostate Cancerovertreatmentprostate cancer

Identifiers

PMID34014592
PMCPMC8353900
OpenAlexW3163288668

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.